Moleculin Biotech, Inc.

HOUSTON, TX · Founded 2015 · CIK 0001659617 · Biotech · Public

Small-molecule cancer therapeutics developed through proprietary drug discovery platforms

moleculin.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$6.0M
1 Form D · May 2016
125 months since last filing
Contracts
—
No federal contracts on record
Patents
5
2 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2313FabricNano Inc.—$21M
2314HALO BIOSCIENCES, INC.——
2315Bond Biosciences, Inc.—$18M
2316Moleculin Biotech, Inc.—$6.0M
2317ProtoKinetix, Inc.—$3.8M
2318CERO THERAPEUTICS HOLDINGS, INC.—$16M
2319INMUNE BIO, INC.—$8.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Walter KlempDirector · Executive Officer
  • Louis PlothExecutive Officer

Patents

USPTO · 2 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.